CYTOKINETICS, INCORPORATED COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • November 6th, 2020 • Cytokinetics Inc • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of July 14, 2020 (the “Closing Date”) by and between Cytokinetics, Incorporated, a Delaware corporation (the “Company”), and [•], with a business address located at [•] (the “Investor”).
LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • November 6th, 2020 • Cytokinetics Inc • Pharmaceutical preparations • New York
This License and Collaboration Agreement (this “Agreement”) is made as of July 14, 2020 (the “Effective Date”), by and between Cytokinetics, Incorporated, a Delaware corporation with a place of business at 280 East Grand Avenue, South San Francisco, CA 94080, USA (“Cytokinetics”), and Ji Xing Pharmaceuticals Limited, a company organized under the laws of the Cayman Islands, with a business address located at [*] (“Ji Xing”). Cytokinetics and Ji Xing are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
Royalty Purchase Agreement By and Between Cytokinetics, Incorporated and Dolya Holdco 19 Designated Activity CompanyRoyalty Purchase Agreement • November 6th, 2020 • Cytokinetics Inc • Pharmaceutical preparations • New York
This Royalty Purchase Agreement, dated as of July 14, 2020 (this “Agreement”), is made and entered into by and between Cytokinetics, Incorporated, a Delaware corporation (the “Seller”), on the one hand, and Dolya Holdco 19 Designated Activity Company (in the process of changing its name to RTW Royalty Holdings Designated Activity Company), a designated activity company incorporated under the laws of Ireland under company number 669527 and whose registered office is at [*] (the “Buyer”), on the other hand.
THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • November 6th, 2020 • Cytokinetics Inc • Pharmaceutical preparations
THIS THIRD AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of July 16, 2020, by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise party thereto from time to time (each a “Lender” and collectively, the “Lenders”) including Oxford in its capacity as a Lender and SILICON VALLEY BANK, a California corporation with an office located at 3003 Tasman Drive, Santa Clara, CA 95054 (“Bank” or “SVB”) (each a “Lender” and collectively, the “Lenders”), and CYTOKINETICS, INCORPORATED, a Delaware corporation with offices located at 280 East Grand Avenue, South San Francisco, CA 94080 (“Borrower”).
Funding Agreement By and Between Cytokinetics, Incorporated and Dolya Holdco 19 Designated Activity Company Dated as of July 14, 2020Funding Agreement • November 6th, 2020 • Cytokinetics Inc • Pharmaceutical preparations • New York
This Funding Agreement, dated as of July 14, 2020, (this “Agreement”), is made and entered into by and between Dolya Holdco 19 Designated Activity Company, a designated activity company incorporated under the laws of Ireland under company under 669527 (the “Buyer”), and Cytokinetics, Incorporated, a Delaware corporation (the “Seller”).
